IMR Press / FBL / Volume 13 / Issue 1 / DOI: 10.2741/2679

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Making the heart resistant to infarction: how can we further decrease infarct size?
Show Less
1 INSERM, Unite 841, Creteil, F-94000 France ; Ecole Nationale Veterinaire d’Alfort, Maisons-Alfort, F-94704 France
2 Department of Cardiology, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany
3 Department of Physiology, University of South Alabama, College of Medicine, Mobile, AL 36688
4 Department of Medicine, University of South Alabama, College of Medicine, Mobile, AL 36688

Academic Editors: Zhelong Xu, Zhelong Xu

Front. Biosci. (Landmark Ed) 2008, 13(1), 284–301;
Published: 1 January 2008
(This article belongs to the Special Issue New strategies for cardioprotection)

Acute myocardial infarction (AMI) following coronary artery occlusion is a common cause of mortality and morbidity world-wide. Patients currently receive reperfusion therapy as the only anti-infarct intervention. A number of agents have been evaluated to further improve myocardial salvage, but until recently, none has demonstrated clear efficacy in clinical trials. A new target of cardioprotection, the Reperfusion Injury Salvage Kinase (RISK) pathway, has been proposed. These kinases are involved in mediating the cardioprotection of myocardial preconditioning and postconditioning induced by short non-lethal cycles of ischemia/reperfusion performed before (preconditioning) or just after (postconditioning) a lethal ischemic insult. Many pharmacological interventions are now available that protect the heart by activating the RISK pathway at the time of reperfusion. The present review will examine the efficacy of several strategies that have been proposed to protect the acutely ischemic myocardium including (1) those intended to directly alter adverse reperfusion events (e.g., calcium overload and free radical attack), (2) those based on activation of the RISK pathway including postconditioning, and (3) myocardial cooling.

Back to top